Phaseline

Companies › Shanghai AbelZeta

Shanghai AbelZeta: clinical trials, targets and expected readouts

4 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
A-CAR032
dnTGFβRII-armoured STEAP2-targeted CAR T cell therapy
STEAP2Phase 1Prostate CancerJan 2027
Prizloncabtagene autoleucel
4-1BB bispecific CAR-T cell targeting CD19 and CD20
CD19, CD20Phase 1Relapsed/Refractory Large B-Cell LymphomaMar 2027
C-CAR031
Armored and GPC3-targeted autologous CAR T-cell therapy
–Phase 1Squamous Cell Lung Cancer; Hepatocellular CarcinomaApr 2027
C-CAR088
BCMA-directed CAR-T cell therapy
BCMAPhase 1Multiple MyelomaJul 2037

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07344311A-CAR032Phase 1Prostate CancerOncologyJan 2027
NCT05800977Prizloncabtagene autoleucelPhase 1Relapsed/Refractory Large B-Cell LymphomaOncologyMar 2027
NCT07444281C-CAR031Phase 1Squamous Cell Lung CancerOncologyApr 2027
NCT06590246C-CAR031Phase 1Hepatocellular CarcinomaOncologyApr 2030
NCT05521802C-CAR088Phase 1Multiple MyelomaOncologyJul 2037

Targets

CD19 (1) CD20 (1) STEAP2 (1) BCMA (1)

Companies with the same targets

Gilead Sciences AstraZeneca Chongqing Precision Biotech Bristol-Myers Squibb iCell Gene Therapeutics Roche Allogene Therapeutics Miltenyi Biomedicine Kali Therapeutics Poseida Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.